Acloproxalap
目录号 : GC68613Acloproxalap 是一种基于喹啉的醛清除剂，可用于有毒醛积累的疾病研究，如眼部、皮肤等炎症性疾病，肺炎等呼吸系统疾病，器官疾病以及病毒感染相关性综合症等。
Cas No.:1824609-67-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Acloproxalap is a quinoline-based aldede scavenger that can be used in studies of diseases with toxic aldede accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes[1][2].
Acloproxalap (compound I-6) (100 or 200 mg/kg, i.p. or p.o., everyday, 6 days) can effectively improve inflammation of the colon in acute ulcerative colitis (UC) female Swiss Webster mice[1].
| Animal Model: | Acute ulcerative colitis (UC) in female Swiss Webster mice[1] |
| Dosage: | 100 mg/kg, 200 mg/kg |
| Administration: | Intraperitoneal injection for 100 mg/kg, oral gavage for 200 mg/kg; everyday; 6 days |
| Result: | Inhibited weight loss in intraperitoneal injection mice significantly while there was no significant difference in the oral gavage group compared to the control group. Both significantly reduced colonic histopathological parameters. |
| Animal Model: | Male non-naÏve beagle dogs[2] | ||||||||||||||
| Dosage: | 3 mg/kg | ||||||||||||||
| Administration: | Intravenous injection; once | ||||||||||||||
| Result: | The pharmacokinetic parameters of Acloproxalap (compound I-1)
|
| Animal Model: | Male non-naÏve beagle dogs[2] | ||||||||||||||
| Dosage: | 10 mg/kg | ||||||||||||||
| Administration: | Oral gavage; once | ||||||||||||||
| Result: | The pharmacokinetic parameters of Acloproxalap (compound I-1)
|
[1]. Susan Macdonald, et al. Treatment of inflammatory disorders. US20190105322
[2]. Todd Brady, et al. Pharmaceutical formulations and uses thereof. WO2021231792
| Cas No. | 1824609-67-7 | SDF | Download SDF |
| 分子式 | C12H14N2O | 分子量 | 202.25 |
| 溶解度 | DMSO : 100 mg/mL (494.44 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.9444 mL | 24.7219 mL | 49.4438 mL |
| 5 mM | 0.9889 mL | 4.9444 mL | 9.8888 mL |
| 10 mM | 0.4944 mL | 2.4722 mL | 4.9444 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。